Co-Authors
This is a "connection" page, showing publications co-authored by Guizhen Wu and Wenjie Tan.
Connection Strength
2.680
-
Profiles of SARS-CoV-2 RNA and Antibodies in Inpatients with COVID-19 not Related with Clinical Manifestation: A Single Centre Study. Virol Sin. 2021 10; 36(5):1088-1092.
Score: 0.238
-
Genetic tracing of HCoV-19 for the re-emerging outbreak of COVID-19 in Beijing, China. Protein Cell. 2021 01; 12(1):4-6.
Score: 0.230
-
Genomic characterization of SARS-CoV-2 identified in a reemerging COVID-19 outbreak in Beijing's Xinfadi market in 2020. Biosaf Health. 2020 Dec; 2(4):202-205.
Score: 0.225
-
Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells. Nat Commun. 2020 08 06; 11(1):3910.
Score: 0.224
-
Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020 05 12; 323(18):1843-1844.
Score: 0.220
-
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 02 22; 395(10224):565-574.
Score: 0.216
-
A47 Origin and possible genetic recombination of the middle east respiratory syndrome coronavirus from the first imported case in china: phylogenetics and coalescence analysis. Virus Evol. 2017 Mar; 3(Suppl 1).
Score: 0.177
-
Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China. Emerg Microbes Infect. 2016 Nov 09; 5(11):e113.
Score: 0.173
-
Origin and Possible Genetic Recombination of the Middle East Respiratory Syndrome Coronavirus from the First Imported Case in China: Phylogenetics and Coalescence Analysis. mBio. 2015 Sep 08; 6(5):e01280-15.
Score: 0.159
-
Complete Genome Sequence of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) from the First Imported MERS-CoV Case in China. Genome Announc. 2015 Aug 13; 3(4).
Score: 0.159
-
[Sequencing and Phylogenetic Analyses of Structural and Accessory Proteins of Middle East Respiratory Syndrome Coronavirus from the First Imported Case in China, 2015]. Bing Du Xue Bao. 2015 Jul; 31(4):333-40.
Score: 0.157
-
One Hundred Days of Coronavirus Disease 2019 Prevention and Control in China. Clin Infect Dis. 2021 01 27; 72(2):332-339.
Score: 0.058
-
Immune suppression in the early stage of COVID-19 disease. Nat Commun. 2020 11 17; 11(1):5859.
Score: 0.057
-
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021 01; 21(1):39-51.
Score: 0.057
-
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020 08 06; 182(3):713-721.e9.
Score: 0.055
-
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. 2020 06 12; 368(6496):1274-1278.
Score: 0.055
-
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020 07; 583(7818):830-833.
Score: 0.055
-
Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science. 2020 05 29; 368(6494):1016-1020.
Score: 0.055
-
Age-related rhesus macaque models of COVID-19. Animal Model Exp Med. 2020 Mar; 3(1):93-97.
Score: 0.055
-
A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 02 20; 382(8):727-733.
Score: 0.054